TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30571206

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance
Number of subjects: 8582

Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 8582
Study: 30571323

Group type: EXPERIMENTAL
Intervention: Increase in Carotid Temperature Heterogeneity
Number of subjects: 0
Study: 30571333

Group type: EXPERIMENTAL
Intervention: Body weight variability (measured as average successive variability)
Number of subjects: 6408

Group type: COMPARATOR
Intervention: Body weight variability (highest quintile vs lowest quintile)
Number of subjects: 6408
Study: 30571334

Group type: EXPERIMENTAL
Intervention: MI-Collaborative hospitals (n=33)
Number of subjects: 911754

Group type: EXPERIMENTAL
Intervention: MI-CollaborativeOnly hospitals (n=15)
Number of subjects: 911754

Group type: EXPERIMENTAL
Intervention: MI-CollaborativePlus hospitals (n=18)
Number of subjects: 911754

Group type: COMPARATOR
Intervention: STS-nonMI hospitals
Number of subjects: 911754
Study: 30571347

Group type: EXPERIMENTAL
Intervention: HEART Pathway implementation
Number of subjects: 8474

Group type: EXPERIMENTAL
Intervention: Postimplementation cohort
Number of subjects: 8474
Study: 30571400

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 285292

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 285292

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 285292
Study: 30571492

Group type: EXPERIMENTAL
Intervention: Self-reported weights at ages 20 and 40 years
Number of subjects: 6437
Study: 30571553

Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Children with high-normal BP
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Children with BP in hypertensive range
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Normotensive peers
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Children with highest cardiorespiratory fitness
Number of subjects: 1171
Study: 30571969

Group type: EXPERIMENTAL
Intervention: Caspase 1/11 invalidation or pharmacological inhibition by Ac-YVAD-CMK injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 30572275

Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (highest quintile)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (second quintile)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (third quintile)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Whole fruit consumption (fourth quintile)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Whole fruit consumption (lowest quintile)
Number of subjects: 3300
Study: 30572352

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy (EUS-nCLE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Endoscopic ultrasound (EUS) alone
Number of subjects: 33
Study: 30572827

Group type: EXPERIMENTAL
Intervention: Severe hyperemesis gravidarum group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 30572830

Group type: EXPERIMENTAL
Intervention: Patient-related delay
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Healthcare-related delay
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Overall diagnostic delay
Number of subjects: 137

Group type: COMPARATOR
Intervention: Living in Italy for < 5 years vs > 5 years
Number of subjects: 137

Group type: COMPARATOR
Intervention: Extra-pulmonary TB
Number of subjects: 137

Group type: COMPARATOR
Intervention: First contact with general practitioner
Number of subjects: 137
Study: 30572853

Group type: EXPERIMENTAL
Intervention: FSFI questionnaire
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GRISS questionnaire
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SQ-F questionnaire
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of FSFI and SQ-F
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of SQ-F and GRISS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall accuracy of questionnaires
Number of subjects: 50
Study: 30572868

Group type: EXPERIMENTAL
Intervention: Faces Pain Scale-Revised (FPS-R)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Face, Legs, Activity, Cry, Consolability (FLACC) Scale
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Parental interview assessment of moderate/severe pain
Number of subjects: 426
Study: 30572891

Group type: EXPERIMENTAL
Intervention: Smartphone app-based medication reporting
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: App-based symptoms reporting
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Duration of smartwatch data streaming
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Performance of structured motor tasks at home
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Predefined schedules and app-based reminders
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Compliance rate for HD patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Compliance rate for PD patients
Number of subjects: 68
Study: 30572920

Group type: EXPERIMENTAL
Intervention: Aedes aegypti salivary gland homogenate antibody intensity determinations by ELISA assays
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Serosurveillance for dengue seroconversion
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Diagnostic tests for acute dengue, Zika, and chikungunya viral infections by RT-PCR
Number of subjects: 771
Study: 30572922

Group type: EXPERIMENTAL
Intervention: LCAR-B38M CAR T cell therapy
Number of subjects: 57
Study: 30573441

Group type: EXPERIMENTAL
Intervention: Remote pulse oximetry system
Number of subjects: 105
Study: 30573448

Group type: EXPERIMENTAL
Intervention: Cell phone support
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Text message support
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Incentives (for nonresponders)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Tapering of interventions (for responders)
Number of subjects: 190
Study: 30573486

Group type: EXPERIMENTAL
Intervention: Smoking cessation support from healthcare professionals
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Number of days of hospitalisation admission in the preceding year
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Patients' perceived correlation between smoking and their illness
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms experienced during hospitalisation
Number of subjects: 382
Study: 30573489

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 0
Study: 30573492

Group type: EXPERIMENTAL
Intervention: Psychotropic medication treatment
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Quality of psychotropic medication treatment
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Mental healthcare utilisation, psychiatric symptomatology, problem behaviour, institutional factors
Number of subjects: 363
Study: 30573564

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with ICE (ifosfamide, carboplatin, etoposide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with ICE/R (ifosfamide, carboplatin, etoposide, and rituximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-agent bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study: 30573690

Group type: EXPERIMENTAL
Intervention: Transgenic adoptive cell therapy (ACT) with dendritic cell (DC) vaccination (ESO cohort)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transgenic adoptive cell therapy (ACT) with dendritic cell (DC) vaccination and ipilimumab (INY cohort)
Number of subjects: 10
Study: 30573970

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 67

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 67
Study: 30574050

Group type: EXPERIMENTAL
Intervention: EL+MV
Number of subjects: 93
Study: 30574327

Group type: EXPERIMENTAL
Intervention: Experts
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Beginners
Number of subjects: 42

Group type: COMPARATOR
Intervention: All observers
Number of subjects: 42
Study: 30574343

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (BID)
Number of subjects: 6897
Study: 30574516

Group type: EXPERIMENTAL
Intervention: ACL-RSI score at preoperative, 4-month, 6-month, 1-year, and 2-year follow-up
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Return to sport (running and the same preinjury sport)
Number of subjects: 681
Study: 30574672

Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg subcutaneously once every 4 weeks for 12 weeks
Number of subjects: 21
Study: 30574833

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 75
Study: 30575051

Group type: EXPERIMENTAL
Intervention: CT ventilation imaging (CTVI) using deformable image registration (DIR) methods classified into B-splines, Free-form, Diffeomorphisms, or Biomechanical modeling.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CT ventilation imaging (CTVI) using various hybrid approaches based on DIR evaluation of volume change, Hounsfield Unit change.
Number of subjects: 50
Study: 30575311

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 174

Group type: COMPARATOR
Intervention: R-galiximab (Anti-CD80)
Number of subjects: 174

Group type: COMPARATOR
Intervention: R-epratuzumab (Anti-CD22)
Number of subjects: 174

Group type: COMPARATOR
Intervention: R-lenalidomide
Number of subjects: 174
Study: 30576085

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg daily
Number of subjects: 75
Study: 30576221

Group type: EXPERIMENTAL
Intervention: Nasal High-Flow Therapy
Number of subjects: 0
Study: 30576664

Group type: EXPERIMENTAL
Intervention: Short-acting methods
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Hispanic ethnicity
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Future pregnancy plans
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Some college education
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Having 2 or more children
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Parents' insurance
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Participants who switched methods
Number of subjects: 2583

Group type: EXPERIMENTAL
Intervention: Reasons for stopping
Number of subjects: 2583
Study: 30576755

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30576970

Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 112
Study: 30577768

Group type: EXPERIMENTAL
Intervention: Phase contrast (PC) MRI following modest exercise challenge
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 30577792

Group type: EXPERIMENTAL
Intervention: Deep infiltrating endometriosis (DIE)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Ovarian endometrioma (OMA)
Number of subjects: 234
Study: 30577883

Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM) questionnaire
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control group (patients who did not undergo colonoscopy)
Number of subjects: 429
Study: 30577927

Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment for depression (PCIT-ED)
Number of subjects: 314
Study: 30577988

Group type: EXPERIMENTAL
Intervention: Buparlisib plus weekly paclitaxel
Number of subjects: 1

Group type: COMPARATOR
Intervention: Systemic chemotherapy, paclitaxel (70 mg/m2)
Number of subjects: 1
Study: 30578023

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily, taken orally without food, until progression or intolerance.
Number of subjects: 36
Study: 30578197

Group type: EXPERIMENTAL
Intervention: Care based on distance monitoring (G_TECCU)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Nurse-assisted telephone care (G_NT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard care (G_Control)
Number of subjects: 63
Study: 30578686

Group type: EXPERIMENTAL
Intervention: Antenatal insulin therapy (AIT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Glycated hemoglobin (HbA1c)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1-hour oral glucose tolerance test (OGTT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HbA1c cut-off value
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 1-hour plasma glucose OGTT cut-off value
Number of subjects: 200
Study: 30578773

Group type: EXPERIMENTAL
Intervention: Participation-focused strategies
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Rehabilitation services
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Having strategies-by-rehabilitation-by-time
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: History of a preexisting condition
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Change in functional capacities at PICU discharge
Number of subjects: 168
Study: 30579045

Group type: EXPERIMENTAL
Intervention: Open-label antidepressant treatment for up to 24 months
Number of subjects: 106
Study: 30579270

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery (CED) using 124I-8H9, a radioimmunotherapeutic agent, with a mean infusate volume of 3.84-4.54 ml.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery (CED) in the highest dose level.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Supratentorial approach to the brainstem crossing the CST.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CED with catheter placement-related adverse events.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CED with Vd-CST overlap analysis.
Number of subjects: 31
Study: 30579327

Group type: EXPERIMENTAL
Intervention: Viscoelastic tests-guided therapy with synthetic factor concentrates
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (before implementation of protocol)
Number of subjects: 237
Study: 30579387

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conditioned pain modulation assay
Number of subjects: 80
Study: 30579407

Group type: EXPERIMENTAL
Intervention: Relative delta power (1-4 Hz) from single-channel EEG
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Relative power from 1 to 6 Hz
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Delirium/possible delirium detection
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Non-delirium days classification
Number of subjects: 159
Study: 30580112

Group type: EXPERIMENTAL
Intervention: vemurafenib
Number of subjects: 3219

Group type: EXPERIMENTAL
Intervention: vemurafenib plus cobimetinib
Number of subjects: 3219
Study: 30580128

Group type: EXPERIMENTAL
Intervention: MAGGIC risk score
Number of subjects: 6859

Group type: COMPARATOR
Intervention: Low-risk group (probability <14%)
Number of subjects: 6859

Group type: COMPARATOR
Intervention: High-risk group (probability >56%)
Number of subjects: 6859

Group type: COMPARATOR
Intervention: Low-risk group (N = 61 dead, 743 alive)
Number of subjects: 6859

Group type: COMPARATOR
Intervention: High-risk group (N = 210 alive, 375 dead)
Number of subjects: 6859
Study: 30580192

Group type: EXPERIMENTAL
Intervention: Home sleep apnea testing (HSAT)
Number of subjects: 236
Study: 30580256

Group type: EXPERIMENTAL
Intervention: STarT Back Tool (SBT) risk group stratification
Number of subjects: 329

Group type: COMPARATOR
Intervention: High risk group (SBT)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: SBT
Number of subjects: 329
Study: 30580418

Group type: EXPERIMENTAL
Intervention: Mandibular repositioning device (MRD) therapy
Number of subjects: 0
Study: 30580559

Group type: EXPERIMENTAL
Intervention: Coronary atherosclerosis imaging
Number of subjects: 0
Study: 30580717

Group type: EXPERIMENTAL
Intervention: Normal flow (43 subjects)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low/borderline flow (23 subjects: 16 low flow, 7 borderline flow)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Hypoperfusion symptoms
Number of subjects: 72

Group type: COMPARATOR
Intervention: Flow status
Number of subjects: 72
Study: 30580723

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy + TOBT
Number of subjects: 89

Group type: COMPARATOR
Intervention: General health education + TOBT
Number of subjects: 89
Study: 30580852

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (mainly vitamin K antagonist)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Stroke/systemic embolism and major bleeding rates
Number of subjects: 1388
Study: 30580992

Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM)
Number of subjects: 1296

Group type: COMPARATOR
Intervention: Normal glycemic status
Number of subjects: 1296

Group type: EXPERIMENTAL
Intervention: Pre-diabetes (pre-DM)
Number of subjects: 1296
Study: 30581606

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg per day for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low- and high-sodium diet cycles (reference test)
Number of subjects: 30
Study: 30581662

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (2 to 3 sessions per week for 12 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 68
Study: 30581893

Group type: EXPERIMENTAL
Intervention: High frequency apheresis (≥20 donations in one year)
Number of subjects: 0
Study: 30582166

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic use (mean 27.8 ± 22.7 days out of 90 days prior to ESS)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Increased preoperative antibiotic use
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic use
Number of subjects: 271
Study: 30582431

Group type: EXPERIMENTAL
Intervention: Full code management group
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: ICU trial (IT) group
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 109
Study: 30582669

Group type: EXPERIMENTAL
Intervention: Three-dimensional magnetic resonance elastography (3D-MRE) with shear stiffness at 60 Hz, damping ratio at 40 Hz, and MRI-PDFF
Number of subjects: 175
Study: 30582928

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) for fetal weight estimation
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ultrasound imaging for fetal weight estimation
Number of subjects: 270
Study: 30583256

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50-100 mg/day)
Number of subjects: 36
Study: 30583899

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (SEP), three times per week for 12 weeks
Number of subjects: 109
Study: 30583927

Group type: EXPERIMENTAL
Intervention: FDG-PET scans at baseline and during CRT
Number of subjects: 21
Study: 30583934

Group type: EXPERIMENTAL
Intervention: Early infancy (sweat chloride concentration)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Late infancy (sweat chloride concentration)
Number of subjects: 59
Study: 30583965

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)
Number of subjects: 92
Study: 30583995

Group type: EXPERIMENTAL
Intervention: AIP cases
Number of subjects: 50
Study: 30584308

Group type: EXPERIMENTAL
Intervention: Tigecycline (initial dose 100 mg, then 50 mg q12h)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (500 mg/500 mg or adjusted for renal dysfunction, q6h)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 470

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 470
Study: 30584317

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin
Number of subjects: 0
Study: 30584583

Group type: EXPERIMENTAL
Intervention: Nebulized Glycopyrrolate
Number of subjects: 0
Study: 30585255

Group type: EXPERIMENTAL
Intervention: SAR405838 200 mg QD plus pimasertib 45 mg BID
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SAR405838 200 mg QD plus pimasertib 60 mg QD or 45 mg BID
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SAR405838 and pimasertib combined
Number of subjects: 26
Study: 30585690

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 14
Study: 30585698

Group type: EXPERIMENTAL
Intervention: One-legged high-intensity interval training (HIIT)
Number of subjects: 20
Study: 30585770

Group type: EXPERIMENTAL
Intervention: MiniMed 670G system with SmartGuard technology in Auto Mode for 3 months
Number of subjects: 105
Study: 30586079

Group type: EXPERIMENTAL
Intervention: Updated biopsychosocial model of successful aging with HIV
Number of subjects: 0
Study: 30586083

Group type: EXPERIMENTAL
Intervention: Cognitive training interventions
Number of subjects: 13
Study: 30586316

Group type: EXPERIMENTAL
Intervention: Sunitinib administered once weekly at 300 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sunitinib administered once every 2 weeks at 700 mg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sunitinib (both dosing schedules)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sunitinib (once every 2 weeks at 700 mg)
Number of subjects: 69
Study: 30586363

Group type: EXPERIMENTAL
Intervention: Lower respiratory tract (LRT) samples
Number of subjects: 115

Group type: COMPARATOR
Intervention: Nasal samples
Number of subjects: 115
Study: 30586692

Group type: EXPERIMENTAL
Intervention: Idarucizumab (5-g dose administered as 2 bolus infusions of 2.5 g no more than 15 minutes apart)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 137
Study: 30586699

Group type: EXPERIMENTAL
Intervention: FFR derived from routine coronary angiography
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Coronary pressure wire and hyperemic stimulus
Number of subjects: 301
Study: 30586721

Group type: EXPERIMENTAL
Intervention: Intraaortic Balloon Pump (IABP)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (no IABP)
Number of subjects: 600